Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABI-H0731 + NrtI
- Development stage
- Unknown
- Lead developer
- Assembly Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ABI-H0731 + NrtI is a **combination therapy** consisting of **ABI-H0731**, a first-generation hepatitis B virus (HBV) core protein inhibitor (also known as a capsid assembly modulator), plus a nucleoside or nucleotide reverse transcriptase inhibitor (NrtI) as standard of care. ABI-H0731 directly targets the HBV core protein, blocking pregenomic RNA (pgRNA) encapsidation and subsequent DNA replication, and suppresses covalently closed circular DNA (cccDNA) formation. NrtIs (e.g., entecavir, tenofovir, lamivudine) act as competitive substrate inhibitors that terminate DNA chain elongation during HBV replication. Together, the combination yields faster and deeper suppression of HBV viral replication than either agent alone, with additive to moderately synergistic effects, as well as a favorable safety and pharmacokinetic profile. This regimen is being developed primarily for the treatment of **chronic hepatitis B**[1][3][5].
- Brand names
- Vebicorvir
- Other names
- ABI H0731
02
Targets
HBc (Hepatitis B virus core protein)HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on ABI-H0731 + NrtI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABI-H0731 + NrtI.